BioWorld

Nov. 13, 2003

As Expected, VaxGen's Second AidsVax Phase III In HIV Misses

VaxGen Inc.'s investigational vaccine for the prevention of HIV infection failed to hit primary or secondary endpoints in a Phase III trial conducted in Thailand. (BioWorld Today) Read More

YM Licenses European Rights To Cancer Drug In $30M Deal

In Seawater, Vibrio cholerae Form Calcium-Dependent Biofilms In Order To Survive

With Phase III Ongoing, Repligen Presents Preclinical Secretin Data

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...